Literature DB >> 15593014

Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages.

Claudia Monari1, Francesco Bistoni, Arturo Casadevall, Eva Pericolini, Donatella Pietrella, Thomas R Kozel, Anna Vecchiarelli.   

Abstract

Glucuronoxylomannan (GXM) is a microbial compound that can modulate the immune response. We investigated (1) the receptors involved in uptake of GXM on monocyte-derived macrophages (MDMs) from healthy donors, (2) the effects of GXM on expression of specific receptors, (3) the effects of GXM mediated by pattern-recognition receptors, and (4) GXM modulation of MDM accessory and secretory functions. Cellular receptors involved in uptake of GXM included Fc gamma RII, CD18, Toll-like receptor (TLR) 4, and CD14. Some biological functions of MDMs were profoundly affected by treatment with GXM, resulting in (1) increased expression of CD40 and CD86 via perturbation of TLR4, (2) decreased expression of major histocompatibility complex class II, (3) induction of interleukin-10 but not of tumor necrosis factor-alpha, and (4) decreased lipopolysaccharide (LPS)-induced production of cytokines. GXM represents an attractive compound to limit inflammatory processes and induce an LPS-tolerant state.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15593014     DOI: 10.1086/426511

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Capsular Material of Cryptococcus neoformans: Virulence and Much More.

Authors:  A Vecchiarelli; C Monari
Journal:  Mycopathologia       Date:  2012-02-08       Impact factor: 2.574

2.  Rat eosinophils stimulate the expansion of Cryptococcus neoformans-specific CD4(+) and CD8(+) T cells with a T-helper 1 profile.

Authors:  Ana P Garro; Laura S Chiapello; José L Baronetti; Diana T Masih
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

3.  Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo.

Authors:  Lauren E Yauch; Michael K Mansour; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.

Authors:  Luis R Martinez; Arturo Casadevall
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 5.  The presence of 3-hydroxy oxylipins in pathogenic microbes.

Authors:  Olihile M Sebolai; Carolina H Pohl; Lodewyk J F Kock; Vishnu Chaturvedi; Maurizio del Poeta
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-11-11       Impact factor: 3.072

6.  Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions.

Authors:  Débora L Oliveira; Célio G Freire-de-Lima; Joshua D Nosanchuk; Arturo Casadevall; Marcio L Rodrigues; Leonardo Nimrichter
Journal:  Infect Immun       Date:  2010-02-09       Impact factor: 3.441

7.  A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock.

Authors:  M Piccioni; C Monari; S Kenno; E Pericolini; E Gabrielli; D Pietrella; S Perito; F Bistoni; T R Kozel; A Vecchiarelli
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

8.  Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection.

Authors:  Loïc Guillot; Scott F Carroll; Robert Homer; Salman T Qureshi
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

Review 9.  Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi.

Authors:  Lisa Brown; Julie M Wolf; Rafael Prados-Rosales; Arturo Casadevall
Journal:  Nat Rev Microbiol       Date:  2015-09-01       Impact factor: 60.633

Review 10.  How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans.

Authors:  Tamara Lea Doering
Journal:  Annu Rev Microbiol       Date:  2009       Impact factor: 15.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.